Create account to read this article for free
Get free access to a limited number of articles.
Uncertainty makes it harder to deal
The biotech industry is currently navigating a storm that has made it difficult to reach agreements. The tariff-related market turbulence has led to enormous uncertainty, where the valuation gap between the parties has become...
Previous chronicles
The venture capital cycle is complete – we are back where we started
There are too many turns – the market needs to rest
Fruergaard Jørgensen is leaving – something is wrong
The first move has been made – now we are waiting for answers
Uncertainty makes it harder to deal
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account